Application

PF-06869206 has been used to selectively inhibit the activity of sodium-phosphate cotransporter 2a (NaPi2a).

Biochem/physiol Actions

PF-06869206 is a selective inhibitor against sodium-phosphate cotransporter 2A (NaPi-2a, NaPi-Iia, Na+/Pi cotransporter 2A, Na+-dependent phosphate cotransporter 2A).

PF-06869206 may be used to treat patients with mineral and hormonal derangements linked with increased cardiovascular risk in chronic kidney disease. This drug might also improve urinary phosphate excretion. PF-06869206 has an ability to decrease phosphate uptake in human embryonic kidney (HEK) cells transfected with mouse or rat renal sodium-dependent phosphate transporter genes (Npt2a).

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc